Tracking

Thursday 24 June 2021

CCC publication: Polatuzumab vedotin with bendamustine and rituximab for relapsed/refractory high-grade B cell lymphoma: the UK experience

Citation: Hematological Oncology. 2021, 39, 1-2
Author:  Northend; Wilson, W.; Osborne, W.; Fox, C. P.; Davies, A. J; El-Sharkawi, D.; Phillips, E. H.; Sim, H. W.; Sadullah, S.; Shah, N.; Peng, Y. Y.; Qureshi, I.; Addada, J.; Mora, R. F.; Phillips, N.; Kuhnl, A.; Davies, E.; Wrench, D.; McKay, P.; Karpha, I.